These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24344010)

  • 1. The prognostic role of interleukin-8 (IL-8) and matrix metalloproteinases -2 and -9 in lymph node-negative untreated breast cancer patients.
    Milovanovic J; Todorovic-Rakovic N; Abu Rabi Z
    J BUON; 2013; 18(4):866-73. PubMed ID: 24344010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Worse prognosis in breast cancer patients can be predicted by immunohistochemical analysis of positive MMP-2 and negative estrogen and progesterone receptors.
    Ramos EA; Silva CT; Manica GC; Pereira IT; Klassen LM; Ribeiro EM; Cavalli IJ; Braun-Prado K; Lima RS; Urban CA; Costa FF; Noronha L; Klassen G
    Rev Assoc Med Bras (1992); 2016 Nov; 62(8):774-781. PubMed ID: 27992019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
    Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
    Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer].
    Zhang B; Liu YX; Cao WF; Cao XC; Ning LS; Hao XS
    Zhonghua Bing Li Xue Za Zhi; 2008 Jul; 37(7):471-6. PubMed ID: 19035119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
    Zhang B; Cao X; Liu Y; Cao W; Zhang F; Zhang S; Li H; Ning L; Fu L; Niu Y; Niu R; Sun B; Hao X
    BMC Cancer; 2008 Mar; 8():83. PubMed ID: 18373849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of progression and invasion in short term follow up of untreated breast cancer patients.
    Rabi ZA; Todorović-Raković N; Vujasinović T; Milovanović J; Nikolić-Vukosavljević D
    Cancer Biomark; 2015; 15(6):745-54. PubMed ID: 26406416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.
    Li HC; Cao DC; Liu Y; Hou YF; Wu J; Lu JS; Di GH; Liu G; Li FM; Ou ZL; Jie C; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2004 Nov; 88(1):75-85. PubMed ID: 15538048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast.
    Sullu Y; Demirag GG; Yildirim A; Karagoz F; Kandemir B
    Pathol Res Pract; 2011 Dec; 207(12):747-53. PubMed ID: 22030137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients.
    Ma Y; Ren Y; Dai ZJ; Wu CJ; Ji YH; Xu J
    Adv Clin Exp Med; 2017; 26(3):421-426. PubMed ID: 28791816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of interleukin 8 and matrix metalloproteinases 2 and 9 in breast cancer treated with tamoxifen.
    Milovanovic J; Todorovic-Rakovic N; Abu Rabi Z
    J BUON; 2017; 22(3):628-637. PubMed ID: 28730767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
    Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
    Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.
    Ahmed SS; Thike AA; Zhang K; Lim JC; Tan PH
    J Clin Pathol; 2017 Apr; 70(4):320-326. PubMed ID: 27612503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
    Ba JL; Liu CG; Jin F
    Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
    Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
    Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.
    Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
    Breast Cancer Res Treat; 1999 Dec; 58(3):287-93. PubMed ID: 10718490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
    Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
    Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.